Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transgenomic has announced that the National Cancer Institute had approved a proposal to perform mutational analysis and sequencing of the mitochondrial genes in the NCI 60 cancer cell line panel.
Subscribe to our email newsletter
This is the first comprehensive evaluation of the mitochondrial genome in the National Cancer Institute (NCI) 60 panel. The data from this study will be a valuable tool for integrating mitochondrial genomics with other data derived from the NCI 60 panel.
Eric Kaldjian, chief scientific officer of Transgenomic, said: “Tens of thousands of compounds have been tested against the NCI 60 cell lines in the NCI’s pharmacological database of cancer drugs. This collaboration makes it possible to test whether in vitro responses to anti-cancer agents are linked to alterations in the mitochondrial genome and can be detected with our sensitive mutation detection technology.”